Richard J Auchus, MD, PhD

Articles by Richard J Auchus, MD, PhD

Expert Perspectives 2024: Breakthrough Therapy for Congenital Adrenal Hyperplasia with PI Richard Auchus, MD, PhD

ByRichard J Auchus, MD, PhD,Grace Halsey

December 17th 2024

The lead investigator of the largest clinical trial program in people with CAH discusses the condition, its burden, and the novel drug just approved that will change lives.

Richard J Auchus, MD, PhD, Details Pivotal Phase 3 Trial That Supported FDA Approval of Crinecerfont for Congenital Adrenal Hyperplasia

ByRichard J Auchus, MD, PhD,Grace Halsey

December 16th 2024

Auchus details findings from the unique study of the CRF-1 antagonist crinecerfont, the first new therapy for CAH approved in 70 years.

Richard J Auchus, MD, PhD

Articles by Richard J Auchus, MD, PhD

Expert Perspectives 2024: Breakthrough Therapy for Congenital Adrenal Hyperplasia with PI Richard Auchus, MD, PhD

Richard J Auchus, MD, PhD, Details Pivotal Phase 3 Trial That Supported FDA Approval of Crinecerfont for Congenital Adrenal Hyperplasia

Latest Updated Articles

Trending on Patient Care Online

New Menopause Therapies Reflect a “Sea Change” in Women’s Health, Says Lisa Larkin, MD

Why Caregivers Don't Talk About Alzheimer Agitation, With Geriatric NP Carolyn Clevenger, GNP

Lifestyle Intervention Shows Benefits Beyond Cognition in US POINTER Trial, Highlighting Modifiable Risk Factors for Dementia

Semaglutide’s Setback in Alzheimer Disease Trials: Commentary on Outcomes of evoke and evoke+

Baxdrostat Granted FDA Priority Review for Hard-to-Control Hypertension, Could Be First-In-Class Therapy